Erenumab

Erenumab is a prescription medication used for the prevention of migraine attacks in adults.

• Erenumab is available under the following different brand names: Aimovig

Adult dosage

Single-dose prefilled syringe

• 70mg/mL
• 140mg/mL

Single-dose prefilled SureClick autoinjector 

• 70mg/mL
• 140mg/mL

Migraine Prophylaxis

Adult dosage

• 70 mg SC once monthly 
• Some patients may need 140 mg SC once monthly (administered as 2 consecutive 70-mg SC doses)

Dosage Considerations – Should be Given as Follows: 

• See "Dosages."

Common side effects of Erenumab include:

• injection site pruritis, erythema or pain,
• constipation,
• cramps, and
• muscle spasms

Serious side effects of Erenumab include:

• oral mucosal ulceration,
• hypersensitivity reactions such as rash, angioedema, or anaphylaxis
• swelling of face, lips, tongue, or throat,
• constipation with serious complications, and
• hypertension

Rare side effects of Erenumab include:

• none 

This is not a complete list of side effects and other serious side effects or health problems that may occur as a result of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Erenumab has no noted severe interactions with any other drugs.
• Erenumab has no noted serious interactions with any other drugs.
• Erenumab has no noted moderate interactions with any other drugs.
• Erenumab has no noted minor interactions with any other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your health care professional or doctor for additional medical advice, or if you have health questions, concerns.

Contraindications

• Hypersensitivity to drug or excipients

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Erenumab?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Erenumab?”

Cautions

• Hypersensitivity reactions (e.g., rash, angioedema, anaphylaxis) reported; may occur within hours or one week following administration; discontinue administration and initiate appropriate therapy if serious reaction occurs
• Hypertension
  • Development of hypertension and worsening of pre-existing hypertension reported
  • Pre-existing hypertension or of risk factors increases risk
  • Pharmacological treatment may be necessary
  • May occur at any time but most frequently within seven days of dose administration
  • Onset or worsening of hypertension usually reported after first dose
  • Monitor for new onset or worsening of pre-existing hypertension and consider whether discontinuation of therapy is warranted if no alternate etiology is found
• Constipation
  • Constipation with serious complications reported in the post-marketing setting; cases that required hospitalization, including cases where surgery was necessary reported
  • In majority cases, the onset of constipation was reported after the first dose; however, patients have also presented with constipation later on in treatment
  • Monitor patients for severe constipation and manage as clinically appropriate
  • Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and potential for constipation-related complications

Pregnancy and Lactation

• Data are not available regarding fetal risk if used in pregnant women
• Clinical considerations
  • Data suggest that women with migraine may be at increased risk of preeclampsia during pregnancy

Lactation

• Data are not available on the presence in human milk, the effects on the breastfed infant, or the effects on milk production
• Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition